FDA drops black-box warnings on three more menopause patches

The US FDA said three more estrogen patches for menopause will no longer carry black-box warnings about cardiovascular disease, breast cancer and dementia. The agency did not convene an advisory committee and gave few details on the evidence. Six treatments lost such warnings in February. Yale researcher Reshma Ramachandran criticised the lack of transparency, warning it may understate real risks.